26 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run https://www.fool.com/investing/2024/03/10/have-2000-2-magnificent-stocks-ready-for-a-bull-ru/?source=iedfolrf0000001 Mar 10, 2024 - These stocks are trading down, but investors may be overlooking some important points.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296 Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
Top Research Reports for Microsoft, Coca-Cola & Accenture https://www.zacks.com/commentary/2241249/top-research-reports-for-microsoft-coca-cola-accenture?cid=CS-ZC-FT-research_daily-2241249 Mar 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), The Coca-Cola Company (KO) and Accenture plc (ACN).
GSK Outperforms Industry on Strength in Key Drugs & Vaccines https://www.zacks.com/stock/news/2243568/gsk-outperforms-industry-on-strength-in-key-drugs-vaccines?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2243568 Mar 20, 2024 - Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062 Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study https://www.zacks.com/stock/news/2246921/moderna-mrna-posts-upbeat-data-from-next-gen-covid-jab-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246921 Mar 27, 2024 - Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID vaccine induces a more robust immune response compared with its previously approved bivalent COVID vaccine.

Pages: 123

<<<Page 3